2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 909

Determinants of Patient Preferences for Total Knee Replacement: A Comparison of Whites and African-Americans
Abstract Number: 1525

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV)
Abstract Number: 1572

Developing a Health Literacy Universal Precautions Toolkit for Rheumatology
Abstract Number: 1713

Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains
Abstract Number: 531

Developmen and Validation of a New Instrument to Asess Health Related Quality of Life in Psoriasis Arthritis: The Vitacora Questionnaire
Abstract Number: 106

Development of a 6 Joint Simplified Ultrasonographic Score to Assess Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1660

Development of a Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA)
Abstract Number: 1376

Development of A Health Index for Patients with Ankylosing Spondylitis – First Steps of A Global Initiative Based On the ICF Guided by ASAS
Abstract Number: 276

Development of a Longitudinal, Propective Cohort of Young Adults with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 37

Development of a Mouse Model of Natural Osteoarthritis of Knee by Induction of obesity and Bipedal Walking
Abstract Number: 32

Development of a Quantitative Model of Endotoxin-Induced Calvarial Bone Erosion Utilizing Micro-Computed Tomography and Pax-It Imaging Analysis Software
Abstract Number: 620

Development of A Quantitative PCR Method to Determine Interferon Signature Metric Status in SLE Patients: Distribution and Clinical & Serological Associations in Two Lupus Clinical Trials
Abstract Number: 1158

Development of Cut-off Values for High Disease Activity in Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis Disease Activity Score
Abstract Number: 1438

Development of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice in the Absence of Any Single BAFF Receptor
Abstract Number: 2220

Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].